First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis

• Alice B. Gottlieb ,

  Contributed equally to this work with: Alice B. Gottlieb, James G. Krueger, Mia Sandberg Lundblad, Marie Göthberg, Brett E. Skolnick

  * E-mail: agottlieb@tuftsmedicalcenter.org

  Affiliations Department of Dermatology, Tufts Medical Center, Boston, MA, United States of America, Department of Dermatology, Tufts University School of Medicine, Boston, MA, United States of America

  ⨯
• James G. Krueger ,

  Contributed equally to this work with: Alice B. Gottlieb, James G. Krueger, Mia Sandberg Lundblad, Marie Göthberg, Brett E. Skolnick

  Affiliation The Rockefeller University, New York, NY, United States of America

  ⨯
• Mia Sandberg Lundblad ,

  Contributed equally to this work with: Alice B. Gottlieb, James G. Krueger, Mia Sandberg Lundblad, Marie Göthberg, Brett E. Skolnick

  Affiliation Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark

  ⨯
• Marie Göthberg ,

  Contributed equally to this work with: Alice B. Gottlieb, James G. Krueger, Mia Sandberg Lundblad, Marie Göthberg, Brett E. Skolnick

  Affiliation Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark

  ⨯
• Brett E. Skolnick

  Contributed equally to this work with: Alice B. Gottlieb, James G. Krueger, Mia Sandberg Lundblad, Marie Göthberg, Brett E. Skolnick

  Current Address: Cushing Neuroscience Institute, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY, United States of America

  Affiliation Medical-Science, Inflammation, Novo Nordisk Inc., Princeton, NJ, United States of America

  ⨯